Navigation Links
Ambry Genetics Launches Illumina HiSeq 2000 Next Generation Sequencing Services
Date:12/9/2010

ALISO VIEJO, Calif., Dec. 9, 2010 /PRNewswire/ -- Ambry Genetics, a global leader in genomic services to the healthcare and life sciences industries, announced today that it has officially launched their Illumina HiSeq 2000 Next Generation Sequencing Services. Ambry Genetics has been an early adapter of Illumina sequencing systems since 2007 and has extensive experience as a Certified Service Provider.

(Logo:  http://photos.prnewswire.com/prnh/20090428/LA06744LOGO)

"We've continued to invest and develop our sequencing operations to become Illumina experts," said Ardy Arianpour, Vice President of Business Development at Ambry Genetics.  "All of our customers are excited about the Illumina HiSeq because it expands our whole genome and exome sequencing services to the next level and gives them the opportunity to reduce their costs while providing more data.  If Illumina is your preferred platform then we want to be your preferred sequencing provider."

Ambry Genetics has been at the forefront of applying new sequencing technologies that best meet our clients' needs.  A team of scientists routinely process libraries for all available applications ranging from small RNAs to whole genome DNA sequencing.  Having sequenced thousands of samples involving a wide range of species including human, mouse, bacteria, viruses, and plants, Ambry is known for its reputation for delivering quality data and service as well as the flexibility in customizing projects to meet the specific needs of researchers.  Ambry Genetics will get your projects done right.

About Ambry Genetics -Ambry Genetics is a CAP-accredited and CLIA-certified commercial clinical laboratory headquartered in Aliso Viejo, California. Since the company's inception in 2000, it has become a leader in providing genetic services focused on clinical diagnostics and genomic services. Ambry has built a solid reputation for unparalleled service, and has been at the forefront of applying new technologies to the clinical molecular diagnostics market and advancements in disease research. To learn more about testing and services available through Ambry, visit www.ambrygen.com


'/>"/>
SOURCE Ambry Genetics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambry Genetics Becomes First Certified Service Provider in US for NimbleGen SeqCap EZ Exome
2. Ambry Genetics Announces the Addition of Illumina HiSeq 2000 and First 510(K) Approved BeadXpress® to Its Sequencing and Genotyping Capabilities
3. Ambry Genetics Introduces AmbryScreen(TM), a Genetic Test Screening for Some of the Most Common and Severe Genetic Disorders Affecting Newborns.
4. Ambry Genetics and RainDance Technologies Announce Partnership for Diagnostics and Genomics Services Utilizing the RDT 1000 for Sequence Enrichment and Targeted Resequencing Validation
5. Ambry Genetics Announces Launch of Their StemArray(TM) Product and Services for High Resolution Characterization of Human Stem Cells
6. Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects
7. London Genetics and Astrimmune to Collaborate on Cancer Vaccine
8. Interleukin Genetics Reports Third Quarter 2010 Financial Results
9. Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
10. New England Biolabs Launches a Suite of Innovative Tools to Advance Epigenetics Research, Including PCR-Based Assay to Identify and Quantitate 5-hmC in Epigenome
11. Diaceutics and London Genetics Partner to Accelerate Biomarker Development in the Global Biopharmaceutical Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and Company ... of its phase 3 EXPEDITION3 trial at the 9 ... As previously disclosed, solanezumab did not meet the primary ... solanezumab initiated in people with mild dementia due to ... submissions for solanezumab for the treatment of mild dementia ...
(Date:12/8/2016)... CITY , Dec. 8, 2016 ... US patents for improving the accuracy, reproducibility and ... images in long and small bone orthopaedic applications. ... approach to creating personalized orthopaedic restorations based on ... personalized orthopaedic restorations, the company harnesses the world,s ...
(Date:12/8/2016)... Mass. , Dec. 8, 2016  EIP ... it has obtained proof-of-mechanism for neflamapimod (previously code ... completed Phase 2a clinical trials that demonstrated significant ... Study 302 (12-week treatment) and Study 303 (6-week ... Clinical Trials in Alzheimer,s Disease (CTAD) scientific conference ...
Breaking Medicine Technology:
(Date:12/10/2016)... WASHINGTON, D.C. (PRWEB) , ... December 10, 2016 ... ... children’s Christmas wish lists for Santa are all sources of external stimuli that ... season. For some, the added pressure to spread holiday cheer through gifts, food ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... aural rehabilitation—provided by audiologists—to remain a critical part of public access to hearing ... Administration (FDA) announced this week that, starting immediately, it would no ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch Fund ... (NCADD) is recommending the film Whispering Spirits and its discussion guide for ... as an education tool in the war against teen drug abuse. NCADD is ...
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider of ... a new solution for Emergency Departments (ED) has been added to their portfolio. ... Department examination rooms, and with a simplified pallet of information available to the ...
(Date:12/8/2016)... ... 08, 2016 , ... After enjoying record-breaking attendance at its ... its 33rd Annual Issues & Research Conference, March 2-3, 2017, at the ... conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." ...
Breaking Medicine News(10 mins):